<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a group of disorders characterized by variable cytopenias and ineffective hematopoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>Hematopoietic stem cells (<z:chebi fb="15" ids="50443">HSCs</z:chebi>) and myeloid progenitors in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> have not been extensively characterized </plain></SENT>
<SENT sid="2" pm="."><plain>We transplanted purified human <z:chebi fb="15" ids="50443">HSCs</z:chebi> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> samples into immunodeficient mice and show that <z:chebi fb="15" ids="50443">HSCs</z:chebi> are the disease-initiating cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We identify a recurrent loss of granulocyte-macrophage progenitors (<z:chebi fb="10" ids="17345">GMPs</z:chebi>) in the bone marrow of low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients that can distinguish low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from clinical mimics, thus providing a simple diagnostic tool </plain></SENT>
<SENT sid="4" pm="."><plain>The loss of <z:chebi fb="10" ids="17345">GMPs</z:chebi> is likely due to <z:mp ids='MP_0006042'>increased apoptosis</z:mp> and increased phagocytosis, the latter due to the up-regulation of cell surface calreticulin, a prophagocytic marker </plain></SENT>
<SENT sid="5" pm="."><plain>Blocking calreticulin on low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> myeloid progenitors rescues them from phagocytosis in vitro </plain></SENT>
<SENT sid="6" pm="."><plain>However, in the high-risk <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) stages of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the <z:chebi fb="10" ids="17345">GMP</z:chebi> population is increased in frequency compared with <z:mpath ids='MPATH_458'>normal</z:mpath>, and myeloid progenitors evade phagocytosis due to up-regulation of CD47, an antiphagocytic marker </plain></SENT>
<SENT sid="7" pm="."><plain>Blocking CD47 leads to the selective phagocytosis of this population </plain></SENT>
<SENT sid="8" pm="."><plain>We propose that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:chebi fb="15" ids="50443">HSCs</z:chebi> compete with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="15" ids="50443">HSCs</z:chebi> in the patients by increasing their frequency at the expense of <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis, that the loss of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> myeloid progenitors by programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> and programmed cell removal are, in part, responsible for the cytopenias, and that up-regulation of the "don't eat me" signal CD47 on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> myeloid progenitors is an important transition step leading from low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and, possibly, to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
</text></document>